Drug · DIN 02526182
RYBREVANT
SINGLE-USE VIAL
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since April 26, 2022; first marketed April 26, 2022.
- Drug Identification Number (DIN)
- 02526182
- Company (DIN owner)
- Janssen Inc.Toronto, Ontario, Canada
- Schedule
- Schedule D; Prescription
- Dosage form
- Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Amivantamab L01FX18
- Class
- Human
- Record last updated
- October 6, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| AMIVANTAMAB | 350 MG | 7 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- March 30, 2022: NOC 27857New Drug Submission (NDS)